Top news from 2023 European Respiratory Society International Congress
Click Here to Manage Email Alerts
The 2023 European Respiratory Society International Congress featured lectures and groundbreaking research on a wide variety of respiratory diseases/conditions.
Of the topics discussed, presentations concerning a drug for pulmonary arterial hypertension, the impact of bacteria in dust of daycare centers and CPAP use for reducing the chances of cardiovascular mortality made up the top headlines from Healio’s coverage of the meeting.
Read these and other top news from the 2023 European Respiratory Society International Congress below:
Sotatercept expected to raise life expectancy, lower hospitalizations in PAH
Patients with pulmonary arterial hypertension receiving sotatercept (Merck), a novel activin signaling inhibitor, plus background therapy are expected to live longer, according to results of a simulation model. Read more.
Bacteria in dust of daycare centers linked to likelihood for childhood wheeze
Children attending daycare centers with a dust microbiota profile of Streptococcus and Lactococcus faced an increased likelihood for wheeze, according to study data. Read more.
CPAP reduces risk for cardiovascular death, hospitalizations in patients with OSA
The risk for death and hospitalizations due to cardiovascular disease in patients with obstructive sleep apnea decreased with use of CPAP, results from a population-based longitudinal observational study revealed. Read more.
Current smoking can shorten telomere length, speed up aging process
Current smoking status was related to shortened leucocyte telomere length, signaling faster aging among cigarette smokers, according to results of a Mendelian randomization study. Read more.
Gefapixant yields modest improvements in refractory, unexplained chronic cough vs. placebo
Gefapixant (MK-7264, Merck) only showed small effects vs. placebo on objective cough frequency, cough severity and quality of life among adults with refractory or unexplained chronic cough, according to results of a systematic review and meta-analysis. Read more.
Digital inhaler improves short-term medication adherence, long-term asthma control
Electronic monitoring devices supported short-term adherence to asthma medication, with sustained improvements in asthma control, according to results of the Acceptance study. Read more.
Clinical remission of severe asthma ‘achievable goal’ with mepolizumab
Patients with severe asthma achieved clinical remission based on a four-component definition with 52 weeks of mepolizumab (Nucala, GSK), according a post-hoc analysis of the real-world REDES study. Read more.
Prenatal air pollutant exposure may negatively impact cell processes in healthy newborns
Traffic-related pollutant exposure during pregnancy may negatively impact autophagy in healthy newborns, according to study results. Read more.